Skip to main content
InjuryClaimHub
Mass Tort Claims

Tylenol Autism Lawsuit: How an Appeals Court Revived It

A federal appeals court just reinstated over 500 Tylenol autism lawsuits, reversing the 2024 ruling that had shut the litigation down entirely.

Written by InjuryClaimHub Editorial Team Fact Checked Published Updated
Table of Contents (9 sections)

A federal appeals court just did something genuinely uncommon in mass tort litigation: it revived a case that had already been declared dead. More than 500 Tylenol autism and ADHD lawsuits were dismissed in 2024 after a judge excluded the plaintiffs’ scientific experts — and in July 2026, a federal appeals court reversed that exclusion and sent the cases back.

Quick answer: Lawsuits allege that prenatal exposure to acetaminophen (Tylenol, made by Kenvue, plus store-brand versions sold by retailers like Walmart and CVS) increases the risk of autism spectrum disorder or ADHD, and that the manufacturers failed to adequately warn about it. The federal litigation, MDL No. 3043 before Judge Denise Cote in the Southern District of New York, was dismissed entirely on August 20, 2024 after Judge Cote excluded all five of the plaintiffs’ causation experts. On July 13, 2026, the Second Circuit Court of Appeals reversed that exclusion for three of the five experts, reviving more than 500 cases and sending them back to the district court. The appeals court did not rule that Tylenol causes autism — only that three experts’ methods were reliable enough for a jury to hear. No trial date or settlement exists yet.

What’s Actually Being Alleged

The theory is a failure to warn, not a claim that acetaminophen is unsafe for its ordinary, non-pregnancy uses. Lawsuits allege that Kenvue (which took over Johnson & Johnson’s consumer health brands, including Tylenol, in a 2023 spinoff) and major retailers selling store-brand generic acetaminophen knew or should have known that use during pregnancy carries an elevated risk of a child later being diagnosed with autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD), and that product labeling did not adequately reflect that risk.

From Consolidation to Total Dismissal, in About Two Years

  • October 5, 2022 — the Judicial Panel on Multidistrict Litigation consolidates the first 18 lawsuits (soon growing past 500) into MDL No. 3043, centralized before Judge Denise Cote in the Southern District of New York.
  • December 7, 2023 — a Daubert hearing tests whether five plaintiffs’ experts can establish general causation: that acetaminophen can cause ASD or ADHD at all, as a scientific matter.
  • December 18, 2023 — Judge Cote excludes all five experts, ruling there is “no generally accepted scientific conclusion” that in utero acetaminophen exposure causes either condition.
  • August 20, 2024 — with no admissible causation evidence remaining, Judge Cote grants summary judgment for every defendant, dismissing all roughly 501 pending federal cases.

The Reversal: Three Experts Back In, Two Still Out

After oral argument on November 17, 2025, a three-judge panel of the U.S. Court of Appeals for the Second Circuit issued a 64-page decision on July 13, 2026, written by Circuit Judge Guido Calabresi. The panel drew a sharp line between the five excluded experts rather than reinstating the litigation wholesale:

  • Reinstated: Dr. Andrea Baccarelli (epidemiologist), Dr. Eric Hollander (psychiatrist) and Dr. Brandon Pearson (toxicologist) — the panel found their methods reflected accepted scientific practice, even where other scientists might reasonably reach different conclusions from the same evidence.
  • Still excluded: Dr. Robert Cabrera, for not adequately applying the standard Bradford Hill causation factors, and Dr. Stan Louie, for not reliably explaining the dose-and-duration thresholds underlying his opinion.

This is exactly the kind of ruling our explainer on how mass tort litigation actually works describes as usually decisive: a Rule 702/Daubert ruling on expert admissibility that can end or revive a litigation’s core theory before a single jury hears the underlying facts. It’s worth comparing this outcome with our guide to the NEC baby formula litigation, where a similar Daubert ruling cut the opposite way — excluding experts and ending bellwether cases before trial rather than reviving them. Our guide to the Zantac ranitidine cancer litigation covers a strikingly similar exclusion decided against a different defendant in Delaware state court in April 2026 — with no appellate reversal reported for that one, at least as of this writing.

Not a Ruling That Tylenol Causes Autism

The Second Circuit was explicit that this was an admissibility ruling, not a merits ruling. The panel found only that three experts’ methods were reliable enough that a jury should be allowed to hear and weigh their opinions — not that those opinions are correct. Whether acetaminophen actually causes ASD or ADHD remains a contested scientific question that no court has resolved, and the broader medical and scientific community remains genuinely divided on it.

Not the Same as the 2025 FDA Warning-Label Controversy

This litigation is easy to conflate with a separate, related news story from the year before. On September 22, 2025, the Department of Health and Human Services released a report on the association between prenatal acetaminophen exposure and ASD/ADHD, and the Trump administration directed the FDA to begin a label-change process for acetaminophen products and to launch a public awareness campaign; the FDA has since urged clinicians to minimize acetaminophen use during pregnancy for routine low-grade fevers. But HHS’s own report acknowledged that “a causal relationship has not been established” and that the underlying studies are contradictory. A regulatory label-change process — whatever it eventually concludes — does not resolve the separate legal question at the center of the MDL: whether specific plaintiffs’ expert evidence meets the courtroom standard for proving individual causation. The same general causation dispute now sits at the center of another mass tort covered on this site — see our guide to the Ozempic and Wegovy GLP-1 litigation for a currently pending Rule 702 hearing facing the same basic question in a different drug class.

Where Things Stand Now

The revived cases return to Judge Cote, who is expected to set a new case-management schedule covering any remaining expert discovery, further challenges to the reinstated experts, case-specific causation for individual plaintiffs, and eventually the selection of bellwether cases for trial. No trial date, bellwether selection, or settlement program exists as of this writing. Kenvue’s stock dropped roughly 2% on the day of the ruling. Separately, a Texas Attorney General consumer-protection lawsuit against Johnson & Johnson and Kenvue over Tylenol marketing has survived its own motion to dismiss — but that is a state enforcement action on a distinct legal theory, not part of this federal MDL and not a personal-injury claim.

Practical Steps

  1. Document acetaminophen use specifically during pregnancy — the timing, frequency, dose and trimester, since the failure-to-warn theory depends on exposure during that specific window.
  2. Gather formal diagnostic records for the child’s autism spectrum disorder or ADHD diagnosis, ideally from the diagnosing specialist.
  3. Don’t stop or change a medication your doctor recommended based on litigation or regulatory news — that decision belongs with your treating physician.
  4. Check your state’s specific filing deadline, since claims involving a minor child’s diagnosis often run on a discovery-rule or minor-tolling basis rather than a fixed date.
  5. Don’t assume the 2025 FDA label announcement changes your legal deadline or your case’s strength — it’s a separate regulatory process from the litigation itself.
  6. Consult an attorney experienced in pharmaceutical mass tort litigation, given how recently and significantly the legal landscape here has shifted.

Sources & Further Reading

  • U.S. District Court, Southern District of New York — docket for MDL No. 3043, In re: Acetaminophen – ASD/ADHD Products Liability Litigation, before Senior Judge Denise L. Cote
  • U.S. Court of Appeals for the Second Circuit — July 13, 2026 opinion reversing in part the district court’s exclusion of plaintiffs’ general causation experts
  • U.S. Department of Health and Human Services and U.S. Food and Drug Administration — September 2025 report and subsequent label-change process for acetaminophen and pregnancy
  • See our guides to how mass tort litigation actually works for what a Rule 702/Daubert ruling generally decides, the NEC baby formula litigation for a similar ruling that cut the opposite way, and the Ozempic and Wegovy GLP-1 litigation for another mass tort currently facing its own pivotal causation-evidence hearing

Frequently Asked Questions

What do the Tylenol autism lawsuits actually allege?

That prenatal exposure to acetaminophen — the active ingredient in Tylenol, sold under that brand by Kenvue (formerly part of Johnson & Johnson) and as store-brand generic versions by major retailers including Walmart and CVS — increases the risk that a child will later be diagnosed with autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD), and that the manufacturers and retailers knew or should have known about this risk without adequately warning pregnant women. It is a failure-to-warn theory, not a claim that the drug is unsafe for its other, non-pregnancy uses.

Why were these lawsuits dismissed back in 2024?

Because the judge overseeing the federal litigation excluded the plaintiffs' scientific experts before any case reached a jury. At a Daubert hearing held December 7, 2023, five experts were offered to establish general causation — that acetaminophen can cause ASD or ADHD at all. On December 18, 2023, U.S. District Judge Denise Cote excluded all five, finding their methodologies unreliable and that 'there is no generally accepted scientific conclusion' supporting the link. With no admissible causation evidence left, Judge Cote granted summary judgment for all defendants on August 20, 2024, dismissing all roughly 501 cases then pending in the federal MDL.

What exactly did the appeals court rule in July 2026?

On July 13, 2026, a three-judge panel of the U.S. Court of Appeals for the Second Circuit reversed Judge Cote's exclusion of three of the five experts. Writing for the unanimous panel, Circuit Judge Guido Calabresi found that the methods used by Dr. Andrea Baccarelli (an epidemiologist), Dr. Eric Hollander (a psychiatrist) and Dr. Brandon Pearson (a toxicologist) reflected accepted scientific practice, even though other scientists might reasonably disagree with their conclusions — which is a question for a jury to weigh, not a judge to exclude. The court left in place the exclusion of the other two experts, finding Dr. Robert Cabrera had not adequately applied the standard Bradford Hill causation factors and Dr. Stan Louie had not reliably explained the dose-and-duration thresholds his opinion depended on.

Does this mean a court has found that Tylenol causes autism?

No, and the Second Circuit was explicit about that limitation. This was solely a Rule 702 admissibility ruling — a decision about which expert opinions a jury is allowed to hear, not a finding about whether those opinions are correct. The panel's own language was that the three reinstated experts' methods 'constitute acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree,' which is a considerably narrower statement than a ruling that acetaminophen causes these conditions. The broader scientific and medical community remains genuinely divided on the underlying question.

Is this the same thing as the 2025 news about an FDA warning label?

No — they are related in subject matter but are entirely separate processes. On September 22, 2025, the Department of Health and Human Services released a report on the association between prenatal acetaminophen exposure and ASD/ADHD, and the Trump administration directed the FDA to begin the process of changing the drug's safety label and to launch a public awareness campaign. The FDA has since issued guidance urging clinicians to minimize acetaminophen use during pregnancy for routine low-grade fevers. But HHS's own report acknowledged that 'a causal relationship has not been established' and that the underlying studies are contradictory — and a regulatory label-change process, however it concludes, does not resolve the separate legal question of whether specific plaintiffs' expert evidence meets the courtroom standard for proving causation.

What happens next in the litigation?

The revived cases return to Judge Cote in the Southern District of New York, who is expected to set a new case-management schedule covering any remaining expert discovery, additional challenges to the reinstated experts, case-specific causation issues for individual plaintiffs, and eventually the selection of bellwether cases for trial. As of this writing, no trial date, bellwether selection, or settlement program has been announced — this litigation is now back at a similar procedural stage to several other mass torts on this site before their first bellwether trials, not close to resolution. Kenvue's stock dropped roughly 2% on the day of the ruling, reflecting how the market read the increased legal exposure.

Is a lawsuit like the Texas Attorney General's case part of this same MDL?

No. A separate suit brought by Texas Attorney General Ken Paxton against Johnson & Johnson and Kenvue alleges deceptive trade practices in how Tylenol was marketed — a state consumer-protection enforcement action, not a personal-injury claim on behalf of an individual child. That case has survived a motion to dismiss and proceeds on its own track in Texas state court, entirely separate from the federal MDL and from any individual family's personal-injury claim.

Can I still file a claim, and what evidence actually matters?

Generally yes, subject to your state's statute of limitations — which, because most of these claims involve a minor child's diagnosis, often runs on a discovery-rule or minor-tolling basis rather than a fixed date from birth; see our guide to the NEC baby formula litigation for how those extended deadlines commonly work for infant and childhood injuries. The evidence that matters most: records establishing acetaminophen use specifically during pregnancy (timing, frequency, and trimester), and formal diagnostic records for the child's autism spectrum disorder or ADHD diagnosis. Don't stop taking a medication your own doctor has recommended based on litigation news — that decision belongs with your physician, not a lawsuit's procedural status.

Related Guides

About the Author

InjuryClaimHub Editorial Team

Research & Editorial

The InjuryClaimHub editorial team researches and writes plain-English guides to personal injury and accident claims. Every guide is built from primary sources — statutes, federal regulations, court rules and government data — and cites them so readers can verify the law themselves. We are not attorneys and our guides are not reviewed by one, which is why every guide tells you to confirm deadlines and figures with a licensed attorney in your state.